Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2025-04-25 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司2024年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制审计报告" which translates to "Internal Control Audit Report" for the fiscal year ending December 31, 2024. It is issued by a certified public accounting firm and discusses the audit of the effectiveness of internal controls over financial reporting. The content focuses on the auditor's responsibility, the company's responsibility, inherent limitations of internal control, and the auditor's opinion on the effectiveness of internal controls. The document length is 1258 characters, which is relatively short but contains substantive audit content rather than just an announcement or certification. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, excluding full annual reports. Therefore, the document should be classified as AR. FY 2024
2025-04-25 Chinese
哈药集团股份有限公司十届六次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board of 哈药集团股份有限公司 regarding the approval of the 2024 Annual Report, the 2025 Q1 report, the 2024 Supervisory Board work report, financial budget, profit distribution plan, asset impairment provisions, asset write-offs, internal control evaluation, and internal control audit report. It includes voting results and confirms compliance with laws and regulations. The document is not the full annual report or quarterly report itself but a formal announcement of supervisory board decisions and approvals related to these reports and plans. The document length is short (1497 characters) and it serves as an official announcement of resolutions rather than containing full financial statements or detailed report content. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement of supervisory board resolutions and approvals related to financial reports and company matters, not the reports themselves.
2025-04-25 Chinese
哈药集团股份有限公司关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (中证天通会计师事务所) for auditing services for the fiscal year 2025. It details the qualifications, integrity, independence, and audit fees of the firm, as well as the approval process by the board and audit committee. The document does not contain any financial statements or audit reports themselves, but rather is a formal announcement of the intention and approval to rehire the auditor. The document length is 2500 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this fits the category of an Audit Report / Information announcement, specifically about auditor appointment, which is best classified under Audit Report / Information (AR). FY 2024
2025-04-25 Chinese
哈药集团股份有限公司2024年年度报告_摘要
Annual Report Classification · 100% confidence The document is titled as "哈药集团股份有限公司 2024 年年度报告摘要" which translates to "Harbin Pharmaceutical Group Co., Ltd. 2024 Annual Report Summary." It contains detailed financial data for the year 2024, including total assets, net profit, revenue, and quarterly breakdowns. It also includes company business descriptions, industry analysis, shareholder information, and management assurances about the report's accuracy. The document is over 8,500 characters, indicating it is substantive and not merely an announcement. The presence of audited financial figures and comprehensive business and financial information aligns with the characteristics of an Annual Report. Therefore, this document is classified as an Annual Report (10-K). FY 2024
2025-04-25 Chinese
哈药集团股份有限公司对会计师事务所2024年度履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm for the year 2024, specifically assessing the audit firm 中证天通会计师事务所's qualifications, independence, quality control, and audit work related to 哈药集团股份有限公司's financial reports. It discusses the audit firm's credentials, audit procedures, communication with the previous auditor, and the audit opinion issued (standard unqualified opinion). The document does not contain the actual financial statements or detailed financial data but is an assessment and report on the audit firm's performance and audit process. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and related audit information excluding full annual reports. The document length is under 5,000 characters but is substantive and detailed, not merely an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2024
2025-04-25 Chinese
哈药集团股份有限公司2024年度独立董事述职报告—卢卫红
Board/Management Information Classification · 95% confidence The document is titled '2024 年度独立董事述职报告' which translates to '2024 Annual Independent Director's Work Report'. It details the independent director's personal background, independence statement, attendance and participation in board and committee meetings, review of financial reports and audit reports, communication with auditors and shareholders, and evaluation of governance and remuneration matters. The document is a detailed report on the independent director's duties and activities over the year, including oversight of financial and governance matters. It is not an announcement or a brief summary but a substantive report on management and board oversight activities. This fits best under the category of 'Board/Management Information (MANG)' as it relates to board member activities and governance oversight rather than a full annual report, audit report, or other categories. The document length (5213 characters) and content confirm it is a full report rather than a short announcement or certification. Therefore, the classification is MANG with high confidence.
2025-04-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.